PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Azithromycin-Ampicillin-Amoxicillin Regimen Lengthens Latency in PPROM, Retrospective Cohort Suggests

azithromycinampicillinamoxicillinerythromycinmacrolidebeta-lactampreterm premature rupture of membraneslatency antibioticsretrospective cohortobstetric infectious diseaseantimicrobial stewardship Women's Health / Reproductive

Background Information

Azithromycin extends latency in preterm premature rupture of membranes.

Preterm premature rupture of membranes (PPROM) poses risks for preterm birth. Choosing effective antibiotics can extend pregnancy duration. Antibiotic use reduced 48-hour birth rates (33.6% to 16%, p=0.04) and extended median time to birth. This retrospective study suggests azithromycin and ampicillin can delay birth after PPROM, but applicability may be limited by the study's observational design. In PPROM, azithromycin with ampicillin effectively extends time to birth.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Bosi FC, Müller GC, Vettorazzi J, Vettori DV, da Costa MCB, Sbaraini M, Tomazzoni RR, Valério EG

Citation: Bosi FC, Müller GC, Vettorazzi J, et al. Azithromycin as macrolide of choice in patients with preterm premature rupture of membranes in expectant management. Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia. 2026;48. doi:10.61622/rbgo/2026rbgo38

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.